The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
or contact the nomad/house broker (shore cap). we need to put a fire under these directors who seem far to comfortable and coming out with "well if we were selling widgets it would be easy, selling our tests is hard" and "our target doctors are very busy people who don't have time to look at our products and will often say i can't use this as i have never heard of it" and the utter bolox of stating in may how wonderful sales of cit were at 4 a day to then tell us in jan that they knew that was as good as it was going to be for the rest of 2023....utter bull**** from the ceo. it's like he refuses to appreciate his actual responsibilities here and is telling us stfu because we are too demanding and don't have the skill set he has.
MM99,
Thanks ( I actually got sent that by a friend). Yes it confirms what we have been saying for ages since the people hit the panic button on court case result. Business is good and Lars is delivering. I expect plenty more to come here.
Good stuff Dug,
Bet I know the answer
Dear Dug,
Thank you for your email and the matters you have highlighted which our management team are very aware of.
Unfortunately we are not able to provide updates to you as this could be treated as price sensitive information.
We will update all shareholders via RNS when appropriate.
Blah Blah Blah
I mentioned FAB (another pharma here yesterday, company is running on fumes with little cash in the bank but flying higher every day, today +34%.
OBD (which has two world class products on offer right now collapsing due to funding concerns, FAB is a very similar financial position in incomes and costs and yet its rocketing Up.......you couldn't make it up
Financial highlights (6 months to 30 Sept 2023)
· Revenue of £541k (H1 FY2023: £1.9 million)
· Expenditure on R&D decreased by 60% to £0.18 million (H1 FY2023: £0.45 million)
· Loss of £1.4 million (H1 FY2023: £1.1 million loss)
· Cash position at 30 September 2023 was £0.5 million (31 March 2023: £0.2 million)
MM99,
CAP-XX Recruiting Job Ad posted only yesterday
We are hiring!
We are looking for a detail-oriented and proficient Financial Controller to join the CAP-XX Limited family. You will play a key role in an exciting and fast-growing business that is shaping the future of energy storage around the world.
MM99,
An interesting angle/observation by a poster on advfn.....I think he may be on to something?
The Imperialist19 Jan '24 - 09:26 - 3036 of 3036
If I was a betting man, I would wager that a certain court case has resulted in a flood of opportunities for CPX, as they showcased their products to the world.
Dug,
Do me a favour please, take a look at FAB. Tell me if they are in position to warrant a rising share price compared to OBD at the moment given their financial position?
I just find it odd that OBD contjnues to be smashed up and sold down and yet FAB being is bought up daily.
Any guidance appreciated.
TIA
Hi Dug,
I get that but there's no way this BoD will deliver commercially by themselves, they must know that. Whilst a partner might extract some big % of incomes etc, the global potential would still be huge for OBD. How else will they be able to commercialise PSE and CIRT tests to a scale to meet demand in the millions of tests a year?
Whats is so frustrating is the company bigging up hitting 4 CIRT tests a day last Summer (which is 120 tests a month) and then telling us yesterday it stopped (as expected apparently, shame they never mentioned that before) and has now resumed at 4 tests a day, so no actual growth in CIRT test since last Summer despite bringing in BUPA for them, how does that make any sense or is that the actual UK level of demand?